A meta-analysis of six trials (Poseidon) found no overall survival benefit from adding long-course (24 months) hormone therapy to post-operative radiotherapy. It suggests that a shorter course of 4-6 months is adequate for most men, marking a significant shift towards treatment de-escalation to reduce long-term toxicity without compromising efficacy in this specific setting.

Following high response rates to systemic therapies like EV Pembro, using radiation for bladder preservation is now questioned. It may constitute overtreatment by radiating a now cancer-free organ, while providing no benefit for the systemic micrometastases that are the primary driver of mortality.

The PRESTO trial evaluated adding apalutamide (APA) and abiraterone (Abby) to a standard LHRH analog. The triplet combination arm demonstrated increased toxicity without any additional efficacy gains compared to the doublet arm (LHRH + APA). This finding reinforces that more intensive combination therapy is not always better and can be detrimental in this setting.

Using radiation as a consolidation therapy after chemo has a significant downside. It damages local tissue, limiting future surgical options and often precluding a neobladder reconstruction—a major quality-of-life factor for patients who may relapse later and require surgery.

Instead of basing adjuvant radiation decisions on a patient's initial, pre-treatment tumor stage, clinicians should use the post-neoadjuvant pathological stage (ypTNM). Patients with a major pathologic response (e.g., downstaging from T3 to T1) may be able to safely avoid additional adjuvant radiation therapy.

While bladder preservation is a key goal, there is an unavoidable risk. Forgoing definitive local treatment like surgery means a subset of patients will not be cured by systemic therapy alone and will miss their opportunity for a potentially curative operation, a crucial ethical consideration.

The chemoradiation control arm in SUNRISE 2 performed so well (e.g., 95% 1-year overall survival) that it challenges the long-held belief that surgery is unequivocally superior. This result, alongside other recent studies, suggests chemoradiation should be considered a potent standard-of-care contender for bladder preservation in appropriately selected patients.

By improving response rates before surgery, adding intravesical BCG can reduce the number of patients requiring follow-up adjuvant systemic therapy. This de-escalation strategy limits patients' overall exposure to toxic treatments and their side effects, a key benefit beyond improving primary outcomes.

The success of new treatments like immunotherapy and ADCs leads to more patients achieving a deep response. This high efficacy makes patients question the necessity of a radical cystectomy, a life-altering surgery, creating an urgent need for data-driven, bladder-sparing protocols.